UT Health Science Center-San Antonio: Mesa, Mays Cancer Center Play Role in Getting New Medications for Blood Cancers Approved
November 30, 2021
November 30, 2021
SAN ANTONIO, Texas, Nov. 30 (TNSRes) -- The University of Texas Health Science Center at San Antonio issued the following news release:
With U.S. Food and Drug Administration (FDA) approval in November of a new medication for polycythemia vera (PV), the outlook brightened a bit for patients with that controllable, but chronic, form of blood cancer.
Ruben A. Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Cen . . .
With U.S. Food and Drug Administration (FDA) approval in November of a new medication for polycythemia vera (PV), the outlook brightened a bit for patients with that controllable, but chronic, form of blood cancer.
Ruben A. Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Cen . . .